David Rich

David Rich serves as the Global Head of Cancer Vaccine Programs at CureVac since March 2025. Prior to this role, David held the position of Vice President and Program Leader in Oncology at ITM Isotope Technologies Munich SE from March 2023 to March 2025, and as Vice President and Asset Lead at Oak Hill Bio from June 2022 to March 2023. David's extensive experience in the pharmaceutical industry includes roles at Ipsen, where responsibilities spanned from Vice President of Global Asset Lead in Rare Diseases to Senior Medical Development Director in Oncology, as well as significant positions at INC Research, Astellas Pharma Europe, Novartis, and Wyeth. David has an educational background that includes a Strategic Leadership Programme from Saïd Business School, University of Oxford, an Oncology Recertification course from Harvard Medical School, an MPhil in Immunology from the University of Southampton, and a Bachelor of Science in Biomedical Science from the University of Wolverhampton.